Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: Results of a randomized trial

Transplant Immunology

Volumn 28, Issue 2-3, 2013, Pages 120-126

  Büchler, Matthias ^a,b   Longuet, Hélène ^a,b   Lemoine, Roxane ^a   Herr, Florence ^a   Gatault, Philippe ^a,b   Thibault, Gilles ^a,b   Ternant, David ^a,b   Foulon, Christine ^b   Pilorge, Bernadette ^b   Lemay, Djamila ^c   Sung, Crystal ^d   Halimi, Jean Michel ^a,b   Baron, Christophe ^a,b   Lebranchu, Yvon ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c SANOFI   (France)

^d Genzyme   (United States)

Author keywords

Antithymocyte globulin; ATG; Lymphocytes; Pharmacokinetics; Reconstitution; Thymoglobulin

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESEARCH; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84879795558     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.03.001     Document Type: Article

References (22)

1. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (Thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010;70:691-732.
2. Mourad G, Morelon E, Noël C, Glotz D, Lebranchu Y. The role of Thymoglobulin induction in kidney transplantation: an update. Clin Transplant 2012;26:E450-64.
3. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007;19:318-30.
4. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
5. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-74.
6. Morelon E, Lefrancois N, Besson C, Prevautel J, Brunet M, Touraine JL, et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol 2010;23:53-8.
7. Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010;10: 2132-41.
8. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17:2844-53.
9. Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2003;9:460-71.
10. Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996;45:29-32.
11. Call SK, Kasow KA, Barfield R, Madden R, Leung W, Horwitz E, et al. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 2009;15:274-8.
12. Cendales LC, Kanitakis J, Schneeberger S, Burns C, Ruiz P, Landin L, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant 2008;8:1396-400.
13. Buchler M, Hurault de Ligny B, Madec C, Lebranchu Y. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant 2003;17:539-45.
14. Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of Thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002;73:1514-8.
15. Wong W, Agrawal N, Pascual M, Anderson DC, Hirsch HH, Fujimoto K, et al. Comparison of two dosages of Thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006;19:629-35.
16. Kho MML, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimer W. The effect of low and ultra-low dosages of Thymoglobulin on peripheral cell T, B and NK cells in kidney transplant recipients. Transpl Immunol 2012;26:186-90.
17. Agha IA, Rueda J, Alvarez A, Singer GG, Miller BW, Flavin K, et al. Short course induction immunosuppression with Thymoglobulin for renal transplant recipients. Transplantation 2002;73:473-5.
18. Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001;71:460-8.
19. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998;91:2360-8.
20. Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Potschger U, et al. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005;27:532-6.
21. Stauch D, Dernier A, Sarmiento Marchese E, Kunert K, Volk HD, Pratschke J, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One 2009;4:e4709.
22. Penack O, Fischer L, Gentilini C, Nogai A, Muessig A, Rieger K, et al. The type of ATG matters - natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transpl Immunol 2007;18:85-7.